Novel Therapeutic and Prevention Approaches for Schistosomiasis: Review

Journal of Advanced Research

Volumn 4, Issue 5, 2013, Pages 467-478

  El Ridi, Rashika A F ^a   Tallima, Hatem A M ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Arachidonic acid; Excretory secretory products; Schistosoma haematobium; Schistosoma mansoni; Schistosomicides; Type 2 adjuvants

Indexed keywords

EID: 84881666717     PISSN: 20901232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jare.2012.05.002     Document Type: Review

References (200)

1. Steinmann P., Keiser J., Bos R., Tanner M., Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis 2006, 6:411-425.
2. King C.H. Parasites and poverty: the case of schistosomiasis. Acta Trop 2010, 113:95-104.
3. Gray D.J., McManus D.P., Li Y., Williams G.M., Bergquist R., Ross A.G. Schistosomiasis elimination: lessons from the past guide the future. Lancet Infect Dis 2010, 10:733-736.
4. Siddiqui A.A., Siddiqui B.A., Ganley-Leal L. Schistosomiasis vaccines. Hum Vaccin 2011, 7:1192-1197.
5. Utzinger J., Raso G., Brooker S., De Savigny D., Tanner M., Ornbjerg N., et al. Schistosomiasis and neglected tropical diseases: towards integrated and sustainable control and a word of caution. Parasitology 2009, 136:1859-1874.
6. Hotez P.J. The neglected tropical diseases and their devastating health and economic impact on the member nations of the organisation of the Islamic conference. PLoS Negl Trop Dis 2009, 3:e539.
7. Hotez PJ, Savioli L, Fenwick A. Neglected tropical diseases of the middle east and north Africa: review of their prevalence, distribution, and opportunities for control. PLoS Negl Trop Dis 201;6:e1475.
8. Curwen R.S., Wilson R.A. Invasion of skin by schistosome cercariae: some neglected facts. Trends Parasitol 2003, 19:63-66.
9. He Y.X., Salafsky B., Ramaswamy K. Comparison of skin invasion among three major species of Schistosoma. Trends Parasitol 2005, 21:201-203.
10. Rheinberg C.E., Moné H., Caffrey C.R., Imbert-Establet D., Jourdane J., Ruppel A. Schistosoma haematobium, S. intercalatum, S. japonicum, S. mansoni, S. rodhaini in mice: relationship between patterns of lung migration by schistosomula and perfusion recovery of adult worms. Parasitol Res 1998, 84:338-342.
11. Sturrock RF. The parasites and their life cycle. In: Jordan P, Webbe G, Sturrock RF, editors. Human schistosomiasis. Wallingford (UK): CAB International; 1993. p. 1-32.
12. Farid Z. Schistosomes with terminal-spined eggs: pathological and clinical aspects. In: Jordan P, Webbe G, Sturrock RF, editors. Human schistosomiasis. Wallingford (UK): CAB International; 1993. p. 159-93.
13. Andersson K.L., Chung R.T. Hepatic schistosomiasis. Curr Treat Options Gastroenterol 2007, 10:504-512.
14. Burke M.L., Jones M.K., Gobert G.N., Li Y.S., Ellis M.K., McManus D.P. Immunopatho-genesis of human schistosomiasis. Parasite Immunol 2009, 3:163-176.
15. Mbabazi P.S., Andan O., Fitzgerald D.W., Chitsulo L., Engels D., Downs J.A. Examining the relationship between urogenital schistosomiasis and HIV infection. PLoS Negl Trop Dis 2011, 5:e1396.
16. Secor W.E. The effects of schistosomiasis on HIV/AIDS infection, progression and transmission. Curr Opin HIV AIDS 2012, 7:254-259.
17. Strickland G.T. Liver disease in Egypt: hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors. Hepatology 2006, 43:915-922.
18. El-Zayadi A.R., Hepatitis C. Comorbidities affecting the course and response to therapy. World J Gastroenterol 2009, 15:4993-4999.
19. Abruzzi A., Fried B. Coinfection of Schistosoma (Trematoda) with bacteria, protozoa and helminths. Adv Parasitol 2011, 77:1-85.
20. Bueding E., Fisher J. Factors affecting the inhibition of phosphofructokinase activity of Schistosoma mansoni by trivalent organic antimonials. Biochem Pharmacol 1966, 115:1197-1211.
21. Denham D.A., Holdsworth R.J. The effect of metrifonate in vitro on Schistosoma haematobium and Schistosoma mansoni adults. Trans Roy Soc Trop Med Hyg 1971, 65:969.
22. Holmstedt B., Nordgren I., Sandoz M., Sundwall A. Metrifonate. Summary of toxicological and pharmacological information available. Arch Toxicol 1978, 41:3-29.
23. Forsyth D.M. Treatment of urinary schistosomiasis: practice and theory. Lancet 1965, 2:354-358.
24. Bergquist R. Strategies for control of infection and disease: current practice and future potential. Schistosomiasis 2001, 413-467. Imperial College Press, London. A.A.F. Mahmoud (Ed.).
25. Foster R., Cheetham B.L. Studies with the schistosomicide oxamniquine (UK-4271). II. Activity in primates. Trans Roy Soc Trop Med Hyg 1973, 67:685-693.
26. Foster R. A review of clinical experience with oxamniquine. Trans Roy Soc Trop Med Hyg 1987, 81:55-59.
27. Pica-Mattoccia L., Cioli D. Studies on the mode of action of oxamniquine and related schistosomicidal drugs. Am J Trop Med Hyg 1985, 34:112-118.
28. Cioli D., Pica-Mattoccia L., Archer S. Antischistosomal drugs: past, present . and future?. Pharmac Ther 1995, 68:35-85.
29. Davis A. Antischistosomal drugs and clinical practice. In: Jordan P, Webbe G, Sturrock RF, editors. Human schistosomiasis. Wallingford: CAB International; 1993. p. 367-404.
30. Kumar V., Gryseels B. Use of praziquantel against schistosomiasis: a review of current status. Int J Antimicrob Agents 1994, 4:313-320.
31. Xiao S.H., Catto B.A., Webster L.T. Effects of praziquantel on different developmental stages of Schistosoma mansoni in vitro and in vivo. J Infect Dis 1985, 151:1130-1137.
32. Mehlhorn H., Becker B., Andrews P., Thomas H., Frenkel J.K. In vivo and in vitro experiments on the effects of praziquantel on Schistosoma mansoni. A light and electron microscopic study. Arzneim Forsch/Drug Res 1981, 31:544-554.
33. Andrews P. Praziquantel: mechanisms of anti-schistosomal activity. Pharmac Ther 1985, 29:129-156.
34. Day T.A., Bennett J.L., Pax R.A. Praziquantel: the enigmatic antiparasitic. Parasitol Today 1992, 8:342-344.
35. Kohn A.B., Anderson P.A.V., Roberts-Misterly J., Greenberg R.M. Schistosome calcium channel β subunits unusual modulatory effects and potential role in the action of the antischistosomal drug praziquantel. J Biol Chem 2001, 276:36873-36876.
36. Greenberg R.M. Ca2+ signalling, voltage-gated Ca2+ channels and praziquantel in flatworm neuromusculature. Parasitology 2005, 131(Suppl):S97-S108.
37. Jeziorski M.C., Greenberg R.M. Voltage-gated calcium channel subunits from platyhelminths: potential role in praziquantel action. Int J Parasitol 2006, 31(36):625-632.
38. Salvador-Recatalà V., Greenberg R.M. Calcium channels of schistosomes: unresolved questions and unexpected answers. Wiley Interdiscip Rev Membr Transp Signal 2012, 1:85-93.
39. Doenhoff M.J., Cioli D., Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis 2008, 21:659-667.
40. Harder A., Goossens J., Andrews P. Influence of praziquantel and Ca2+ on the bilayer-isotropic-hexagonal transition of model membranes. Mol Biochem Parasitol 1988, 29:55-60.
41. Schepers H., Brasseur R., Goormaghtigh E., Duquenoy P., Ruysschaert J.M. Mode of insertion of praziquantel and derivatives into lipid membranes. Biochem Pharmacol 1988, 37:1615-1623.
42. Lima S.F., Vieira L.Q., Harder A., Kusel J.R. Altered behaviour of carbohydrate-bound molecules and lipids in areas of the tegument of adult Schistosoma mansoni worms damaged by praziquantel. Parasitology 1994, 100:469-477.
43. Fenwick A., Savioli L., Engels D., Bergquist N.R., Todd M.H. Drugs for the control of parasitic diseases: current status and development in schistosomiasis. Trends Parasitol 2003, 19:509-515.
44. Doenhoff M.J., Hagan P., Cioli D., Southgate V., Pica-Mattoccia L., Botros S., et al. Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs. Parasitology 2009, 136:1825-1835.
45. Stothard J.R., Sousa-Figueiredo J.C., Betson M., Green H.K., Seto E.Y., Garba A., et al. Closing the praziquantel treatment gap: new steps in epidemiological monitoring and control of schistosomiasis in African infants and preschool-aged children. Parasitology 2011, 138:1593-1606.
46. Oshish A., AlKohlani A., Hamed A., Kamel N., AlSoofi A., Farouk H., et al. Towards nationwide control of schistosomiasis in Yemen: a pilot project to expand treatment to the whole community. Trans Roy Soc Trop Med Hyg 2011, 105:617-627.
47. Leslie J., Garba A., Oliva E.B., Barkire A., Tinni A.A., Djibo A., et al. Schistosomiais and soil-transmitted helminth control in Niger: cost effectiveness of school based and community distributed mass drug administration. PLoS Negl Trop Dis 2011, 5:e1326.
48. Gryseels B., Mbaye A., De Vlas S.J., Stelma F.F., Guisse F., Van Lieshout L., et al. Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence. Trop Med Intl Hlth 2001, 6:864-873.
49. Raso G., N'Goran E.K., Toty A., Luginbuhl A., Adjoua C.A., Tian-Bi N.T., et al. Efficacy and side effects of praziquantel against Schistosoma mansoni in a community of western Cote d'Ivoire. Trans Roy Soc Trop Med Hyg 2004, 98:18-27.
50. Barakat R., El Morshedy H. Efficacy of two praziquantel treatments among primary school children in an area of high Schistosoma mansoni endemicity, Nile Delta, Egypt. Parasitology 2011, 138:440-446.
51. Fallon P.G., Tao L.F., Ismail M.M., Bennett J.L. Schistosome resistance to praziquantel: fact or artifact?. Parasitol Today 1996, 12:316-320.
52. Bennett J.L., Day T., Feng-Tao L., Ismail M., Farghaly A. The development of resistance to anthelmintics: a perspective with an emphasis on the antischistosomal drug praziquantel. Exp Parasitol 1997, 87:260-267.
53. Kusel J., Hagan P. Praziquantel - its use, cost and possible development of resistance. Parasitol Today 1999, 15:352-354.
54. Ismail M., Botros S., Metwally A., William S., Farghally A., Tao L.F., et al. Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am J Trop Med Hyg 1999, 60:932-935.
55. Sabra A.N., Botros S.S. Response of Schistosoma mansoni isolates having different drug sensitivity to praziquantel over several life cycle passages with and without therapeutic pressure. J Parasitol 2008, 94:537-541.
56. Linder E., Thors C. Schistosoma mansoni: praziquantel-induced tegumental lesion exposes actin of surface spines and allows binding of actin depolymerizing factor, gelsolin. Parasitology 1992, 105:71-79.
57. Tallima H., El Ridi R. Praziquantel binds Schistosoma mansoni adult worm actin. Int J Antimicrob Agents 2007, 29:570-575.
58. Tallima H., El Ridi R. Re: is actin the praziquantel receptor?. Int J Antimicrob Agents 2007, 30:566-567.
59. Pica-Mattoccia L., Valle C., Basso A., Troiani A.R., Vigorosi F., Liberti P., et al. Cytochalasin D abolishes the schistosomicidal activity of praziquantel. Exp Parasitol 2007, 115:344-351.
60. Gnanasekar M., Salunkhe A.M., Mallia A.K., He Y.X., Kalyanasundaram R. Praziquantel affects the regulatory myosin light chain of Schistosoma mansoni. Antimicrob Agents Chemother 2009, 53:1054-1060.
61. Richard-Lenoble D., Chandenier J., Duong T.H. Antiparasitic treatments in pregnant women and in children in 2003. Med Trop (Mars) 2003, 63:491-497.
62. Liu H., William S., Herdtweck E., Botros S., Dömling A. MCR synthesis of praziquantel derivatives. Chem Biol Drug Des 2012, 79:470-477.
63. Menezes C.M., Rivera G., Alves M.A., Do Amaral D.N., Thibaut J.P., Noël F., et al. Synthesis, biological evaluation and structure-activity relationship of clonazepam, meclonazepam and 1,4-benzodiazepine compounds with schistosomicidal activity. Chem Biol Drug Des 2012, 79:943-949.
64. N'Goran E.K., Utzinger J., Gnaka H.N., Yapi A., N'Guessan N.A., Kigbafori S.D., et al. Randomized, double-blind, placebo-controlled trial of oral artemether for the prevention of patent Schistosoma haematobium infections. Am J Trop Med Hyg 2003, 68:24-32.
65. Utzinger J., Chollet J., You J., Mei J., Tanner M., Xiao S. Effect of combined treatment with praziquantel and artemether on Schistosoma japonicum and Schistosoma mansoni in experimentally infected animals. Acta Trop 2001, 80:9-18.
66. Utzinger J., Keiser J., Shuhua X., Tanner M., Singer B.H. Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials. Antimicrob Agents Chemother 2003, 47:1487-1495.
67. Mahmoud M.R., Botros S.S. Artemether as adjuvant therapy to praziquantel in murine Egyptian Schistosomiasis mansoni. J Parasitol 2005, 91:175-178.
68. Botros S.S., Hammam O., Mahmoud M., Bergquist R. Praziquantel efficacy in mice infected with PZQ non-susceptible S. mansoni isolate treated with artemether: parasitological, biochemical and immunohistochemical assessment. APMIS 2010, 118:692-702.
69. El-Lakkany N.M., Hammam O.A., El-Maadawy W.H., Badawy A.A., Ain-Shoka A.A., Ebeid F.A. Anti-inflammatory/anti-fibrotic effects of the hepatoprotective silymarin and the schistosomicide praziquantel against Schistosoma mansoni-induced liver fibrosis. Parasit Vectors 2012, 5:9.
70. Chen B.L., Zhang G.Y., Wang S.P., Li Q., Xu M.H., Shen Y.M., et al. The combined treatment of praziquantel with osteopontin immunoneutralization reduces liver damage in Schistosoma japonicum-infected mice. Parasitology 2012, 139:522-529.
71. Xiao S., Tanner M., N'Goran E.K., Utzinger J., Chollet J., Bergquist R., et al. Recent investigations of artemether, a novel agent for the prevention of schistosomiasis japonica, mansoni and haematobia. Acta Trop 2002, 82:175-181.
72. Xiao S.H., Catto B.A. In vitro and in vivo studies of the effect of artemether on Schistosoma mansoni. Antimicrob Agents Chemother 1989, 33:1557-1562.
73. Xiao S., Utzinger J., Chollet J., Endriss Y., N'Goran E.K., Tanner M. Effect of artemether against Schistosoma haematobium in experimentally infected hamsters. Int J Parasitol 2000, 30:1001-1006.
74. Utzinger J., Xiao S.H., Tanner M., Keiser J. Artemisinins for schistosomiasis and beyond. Curr Opin Investig Drugs 2007, 8:105-116.
75. Abdul-Ghani R., Loutfi N., Sheta M., Hassan A. Artemether shows promising female schistosomicidal and ovicidal effects on the Egyptian strain of Schistosoma mansoni after maturity of infection. Parasitol Res 2011, 108:1199-1205.
76. Keiser J., Chollet J., Xiao S.H., Mei J.Y., Jiao P.Y., Utzinger J., et al. Mefloquine - an aminoalcohol with promising antischistosomal properties in mice. PLoS Negl Trop Dis 2009, 3:e350.
77. Keiser J.M., Vargas M., Doenhoff M.J. Activity of artemether and mefloquine against juvenile and adult Schistosoma mansoni in athymic and immunocompetent NMRI mice. Am J Trop Med Hyg 2010, 82:112-114.
78. Xiao S.H., Keiser J., Chollet J., Utzinger J., Dong Y., Endriss Y., et al. In vitro and in vivo activities of synthetic trioxolanes against major human schistosome species. Antimicrob Agents Chemother 2007, 51:1440-1445.
79. Botros S., William S., Hammam O., Zídek Z., Holý A. Activity of 9-(S)-[3-hydroxy-2- (phosphonomethoxy)propyl]adenine against Schistosomiasis mansoni in mice. Antimicrob Agents Chemother 2003, 47:3853-3858.
80. Botros S.S., William S., Beadle J.R., Valiaeva N., Hostetler K.Y. Antischistosomal activity of hexadecyloxypropyl cyclic 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl] adenine and other alkoxyalkyl esters of acyclic nucleoside phosphonates assessed by schistosome worm killing in vitro. Antimicrob Agents Chemother 2009, 53:5284-5287.
81. Sayed A.A., Simeonov A., Thomas C.J., Inglese J., Austin C.P., Williams D.L. Identification of oxadiazoles as new drug leads for the control of schistosomiasis. Nat Med 2008, 14:407-412.
82. Prast-Nielsen S., Huang H.H., Williams D,L. Thioredoxin glutathione reductase: its role in redox biology and potential as a target for drugs against neglected diseases. Biochim Biophys Acta 2011, 1810:1262-1271.
83. Portela J., Boissier J., Gourbal B., Pradines V., Collière V., Coslédan F., et al. Antischistosomal activity of trioxaquines: in vivo efficacy and mechanism of action on Schistosoma mansoni. PLoS Negl Trop Dis 2012, 6(2):e1474.
84. Neves J.K., de Lima Mdo C., Pereira V.R., de Melo C.M., Peixoto C.A., Pitta Ida R., et al. Antischistosomal action of thioxo-imidazolidine compounds: an ultrastructural and cytotoxicity study. Exp Parasitol 2011, 128:82-90.
85. Pierce RJ, Dubois-Abdesselem F, Caby S, Trolet J, Lancelot J, Oger F, et al. Chromatin regulation in schistosomes and histone modifying enzymes as drug targets. Mem Inst Oswaldo Cruz 201;106:794-801.
86. Moraes J., Nascimento C., Lopes P.O., Nakano E., Yamaguchi L.F., Kato M.J., et al. Schistosoma mansoni: in vitro schistosomicidal activity of piplartine. Exp Parasitol 2011, 127:357-364.
87. de Melo NI, Magalhaes LG, de Carvalho CE, Wakabayashi KA, de P Aguiar G, Ramos RC, et al. Schistosomicidal activity of the essential oil of Ageratum conyzoides L. (Asteraceae) against adult Schistosoma mansoni worms. Molecules 2011;16:762-73.
88. Tagboto S., Townson S. Antiparasitic properties of medicinal plants and other naturally-occurring products. Adv Parasitol 2001, 50:199-295.
89. Yousif F, Hifnawy MS, Soliman G, Boulos L, Labib T, Mahmoud S, et al. Large-scale in vitro screening of Egyptian native and cultivated plants for schistosomicidal activity. Pharmaceut Biol 2007;45:501-10.
90. Allegretti SM, Nascimento C, de Oliveira F, de Oliveira RN, Frezza TF, Garcia Rehder VL. The use of Brazilian medicinal plants to combat Schistosoma mansoni. In: Rokni MB, editor. Schistosomiasis. InTechOpen; 2012. p. 27-70. <> [chapter 3]. http://www.intechopen.com/books/schistosomiasis/the-use-of-brazilian-medicinal-plants-to-combat-schistosoma-mansoni.
91. De Moraes J. Antischistosomal natural compounds: present challenges for new drug screens. In: Rodriguez-Morales A, editor. Current topics in tropical medicine. InTech Open; 2012. p. 323-57. <> [chapter 20]. http://www.intechopen.com/books/current-topics-in-tropical-medicine/antischistosomal-natural-compounds-present-challenges-for-new-drug-screens.
92. El-Ansary A.K., Ahmed S.A., Aly S.A. Antischistosomal and liver protective effects of Curcuma longa extract in Schistosoma mansoni infected mice. Indian J Exp Biol 2007, 45:791-801.
93. El-Banhawey M.A., Ashry M.A., El-Ansary A.K., Aly S.A. Effect of curcuma longa or parziquantel on Schistosoma mansoni infected mice liver-histological and histochemical study. Indian J Exp Biol 2007, 45:877-889.
94. Magalhães L.G., Machado C.B., Morais E.R., Moreira E.B., Soares CS., da Silva S.H., et al. In vitro schistosomicidal activity of curcumin against Schistosoma mansoni adult worms. Parasitol Res 2009, 104:1197-1201.
95. Allam G. Immunomodulatory effects of curcumin treatment on murine Schistosomiasis mansoni. Immunobiology 2009, 214:712-727.
96. Luz P.P., Magalhães L.G., Pereira A.C., Cunha W.R., Rodrigues V., Andrade E., et al. Curcumin-loaded into PLGA nanoparticles: preparation and in vitro schistosomicidal activity. Parasitol Res 2012, 110:593-598.
97. Tonkal A.M., Morsy T.A. An update review on Commiphora molmol and related species. J Egypt Soc Parasitol 2008, 38:763-796.
98. Badria F., Abou-Mohamad G., El-Mowafi A., Masoud A., Salama O. Mirazid: a new schistosomicidal drug. Pharma Biol 2001, 39:127-131.
99. Botros S., William S., Ebeid F., Cioli D., Katz N., Day T.A., et al. Lack of evidence for an antischistosomal activity of myrrh in experimental animals. Am J Trop Med Hyg 2004, 71:206-210.
100. Botros S., Sayed H., El-Dusoki H., Sabry H., Rabie I., El-Ghannam M., et al. Efficacy of Mirazid in comparison with praziquantel in Egyptian Schistosoma mansoni-infected school children and households. Am J Trop Med Hyg 2005, 72:119-123.
101. Barakat R., Elmorshedy H., Fenwick A. Efficacy of myrrh in the treatment of human Schistosomiasis mansoni. Am J Trop Med Hyg 2005, 73:365-367.
102. Yakoot M. A short review of the anthelmintic role of Mirazid. Arq Gastroenterol 2010, 47:393-394.
103. Osman M.M., El-Taweel H.A., Shehab A.Y., Farag H.F. Ineffectiveness of myrrh- derivative Mirazid against schistosomiasis and fascioliasis in humans. Eastern Med Health J 2010, 16:932-936.
104. Hockley D.J. Ultrastructure of the tegument of Schistosoma. Adv Parasitol 1973, 11:233-305.
105. Singer S.J., Nicolson G.L. The fluid mosaic model of the structure of cell membranes. Science 1972, 175:720-731.
106. El Ridi R., Mohamed S.H., Tallima H. Incubation of Schistosoma mansoni lung-stage schistosomula in corn oil exposes their surface membrane antigenic specificities. J Parasitol 2003, 89:1064-1067.
107. El Ridi R., Tallima H., Mohamed S.H., Montash M. Depletion of Schistosoma mansoni lung-stage schistosomula cholesterol by methyl-β-cyclodextrin dramatically increases specific antibody binding to surface membrane antigens. J Parasitol 2004, 90:727-732.
108. Tallima H., El Ridi R. Methyl-β-cyclodextrin treatment and filipin staining reveal therole of cholesterol in surface membrane antigen sequestration of Schistosoma mansoni and S. haematobium lung-stage larvae. J Parasitol 2005, 91:720-725.
109. Tallima H., Salah M., El Ridi R. In vitro and in vivo effects of unsaturated fatty acids on Schistosoma mansoni and S. haematobium lung-stage larvae. J Parasitol 2005, 91:1094-1102.
110. El Ridi R., Tallima H. Equilibrium in lung schistosomula sphingomyelin breakdown and biosynthesis allows very small molecules, but not antibody, to access proteins at the host-parasite interface. J Parasitol 2006, 92:730-737.
111. Huwiler A., Kolter T., Pfeilschifter J., Sandhoff K. Review. Physiology and pathophysiology of sphingolipid metabolism and signaling. Biochim Biophys Acta 2000, 1485:63-99.
112. Luberto C., Hassler D.F., Signorelli P., Okamoto Y., Sawai H., Boros E., et al. Inhibition of tumor necrosis factor-induced cell death in MCF7 by a novel inhibitor of neutral sphingomyelinase. J Biol Chem 2002, 277:41128-41139.
113. Hofmann K., Tomiuk S., Wolff G., Stoffel W. Cloning and characterization of the mammalian brain-specific, Mg2+-dependent neutral sphingomyelinase. Proc Natl Acad Sci USA 2000, 97:5895-5900.
114. Robinson B.S., Hii C.S., Poulos A., Ferrante A. Activation of neutral sphingomyelinase in human neutrophils by polyunsaturated fatty acids. Immunology 1997, 91:274-280.
115. Tallima, H. Biochemical exposure of schistosoma surface membrane antigens. Ph.D thesis. Egypt: Faculty of Science, Cairo University; 2006.
116. Tallima H., Al-Halbosiy M.F., El Ridi R. Enzymatic activity and immunolocalization of Schistosoma mansoni and Schistosoma haematobium neutral sphingomyelinase. Mol Biochem Parasitol 2011, 178:23-28.
117. Tallima H., Hamada M., El Ridi R. Evaluation of cholesterol content and impact on antigen exposure in the outer lipid bilayer of adult schistosomes. Parasitology 1997, 134:1775-1783.
118. Brash A.R. Arachidonic acid as a bioactive molecule. J Clin Invest 2001, 107:1339-1345.
119. Zhou L., Nilsson A. Sources of eicosanoid precursor fatty acid pools in tissues. J Lipid Res 2001, 42:1521-1542.
120. Nelson G.J., Kelley D.S., Emken E.A., Phinney S.D., Kyle D., Ferretti A. A human dietary arachidonic acid supplementation study conducted in a metabolic research unit: rationale and design. Lipids 1997, 32:415-420.
121. Roberts MD, Iosia M, Kerksick CM, Taylor LW, Campbell B, Wilborn CD, et al. Effects of arachidonic acid supplementation on training adaptations in resistance-trained males. J Int Soc Sports Nutr 2007;28(4):21-34.
122. Simopoulos A. Evolutionary aspects of diet and essential fatty acids. World Rev Nutr Diet 2001, 88:18-27.
123. Simopoulos A. Evolutionary aspects of diet, essential fatty acids and cardiovascular disease. Eur Heart J Suppl 2001;3(Suppl D):D8-21.
124. Hempenius R.A., Van Delft J.M.H., Prinsen M., Lina B.A.R. Preliminary safety assessment of an arachidonic acid-enriched oil derived from Mortierella alpina: summary of toxicological data. Food Chem Toxicol 1997, 35:573-581.
125. El Ridi R., Aboueldahab M., Tallima H., Salah M., Mahana N., Fawzi S., et al. In vitro and in vivo activities of arachidonic acid against Schistosoma mansoni and Schistosoma haematobium. Antimicrob Agents Chemother 2010, 4:3383-3389.
126. El Ridi R., Tallima H., Salah M., Aboueldahab M., Fahmy O.M., Farhan Al-Halbosiy M., et al. Arachidonic acid efficacy and mechanism of action in treatment of hamsters infected with Schistosoma mansoni or S. haematobium. Int J Antimicrobial Agents 2012, 39:232-239.
127. Dean D.A. A review. Schistosoma and related genera: Acquired resistance in mice. Exp Parasitol 1983, 55:1-104.
128. Butterworth A.E., Capron M., Cordingley J.S., Dalton P.R., Dunne D.W., Kariuki H.C., et al. Immunity after treatment of human schistosomiasis mansoni. II. Identification of resistant individuals, and analysis of their immune responses. Trans Roy Soc Trop Med Hyg 1985, 79:393-408.
129. Hagan P., Blumenthal U.J., Chaudri M., Greenwood B.M., Hayes R.J., Hodgson I., et al. Resistance to reinfection with Schistosoma haematobium in Gambian children: analysis of their immune responses. Trans Roy Soc Trop Med Hyg 1987, 81:938-946.
130. Dessein A.J., Begley M., Demeure C., Caillol D., Fueri J., dos Reis M.G., et al. Human resistance to Schistosoma mansoni is associated with IgG reactivity to a 37-kDa larval surface antigen. J Immunol 1988, 140:2727-2736.
131. Correa-Oliveira R., Pearce E.J., Oliveira G.C., Golgher D.B., Katz N., Bahia L.G., et al. The human immune response to defined immunogens of Schistosoma mansoni: elevated antibody levels to paramyosin in stool-negative individuals from two endemic areas in Brazil. Trans Roy Soc Trop Med Hyg 1989, 83:798-804.
132. Hagan P., Blumenthal U.J., Dunn D., Simpson A.J.G., Wilkins H.A. Human IgE, IgG4 and resistance to reinfection with Schistosoma haematobium. Nature 1991, 349:243-245.
133. Viana I.R., Sher A., Carvalho O.S., Massara C.L., Eloi-Santos S.M., Pearce E.J., et al. Interferon-gamma production by peripheral blood mononuclear cells from residents of an area endemic for Schistosoma mansoni. Trans Roy Soc Trop Med Hyg 1994, 88:466-470.
134. El Ridi R., Farouk F., Sherif M., Al-Sherbiny M., Osman A., El Gengehi N., et al. T and B cell reactivity to a 42-kDa protein is associated with human resistance to both Schistosomiasis mansoni and haematobium. J Infect Dis 1998, 177:1364-1372.
135. El Ridi R, Shoemaker CB, Farouk F, El Sherif NH, Afifi A. Human T- and B-cell responses to Schistosoma mansoni recombinant glyceraldehyde 3-phosphate dehydrogenase correlate with resistance to reinfection with S. mansoni or Schistosoma haematobium after chemotherapy. Infect Immun 2001;69:237-44.
136. Soisson L.M., Masterson C.P., Tom T.D., McNally M.T., Lowell G.H., Strand M. Induction of protective immunity in mice using a 62-kDa recombinant fragment of a Schistosoma mansoni surface antigen. J Immunol 1992, 149:3612-3620.
137. Soisson L.A., Reid G.D.F., Farah I.O., Nyindo M., Strand M. Protective immunity in baboons vaccinated with a recombinant antigen or radiation-attenuated cercariae of Schistosoma mansoni is antibody-dependent. J Immunol 1993, 151:4782-4789.
138. Balloul J.M., Sondermeyer P., Dreyer D., Capron M., Grzych J.M., Pierce R.J., et al. Molecular cloning of a protective antigen of schistosomes. Nature 1987, 326:149-153.
139. Boulanger D., Reid G.D., Sturrock R.F., Wolowczuk I., Balloul J.M., Grezel D., et al. Immunization of mice and baboons with the recombinant Sm28GST affects both worm viability and fecundity after experimental infection with Schistosoma mansoni. Parasite Immunol 1991, 13:473-490.
140. Harn D.A., Mitsuyama M., Huguenel E.D., Oligino L., David J.R. Identification by monoclonal antibodies of a major (28kDa) surface membrane antigen of Schistosoma mansoni. Mol Biochem Parasitol 1985, 16:345-354.
141. Harn D.A., Wei G., Oligino L.D., Mitsuyama M., Gebremichael A., Richter D. A protective monoclonal antibody specifically recognizes and alters the catalytic activity of schistosome triose-phosphate isomerase. J Immunol 1992, 148:562-567.
142. Shoemaker C., Gross A., Gebremichael A., Harn D. CDNA cloning and functional expression of the Schistosoma mansoni protective antigen triose-phosphate isomerase. Proc Natl Acad Sci USA 1992, 89:1842-1846.
143. Lanar D.E., Pearce E.J., James S.L., Sher A. Identification of paramyosin as schistosome antigen recognized by intradermally vaccinated mice. Science 1986, 234:593-596.
144. Fonseca C.T., Cunha-Neto E., Goldberg A.C., Kalil J., de Jesus A.R., Carvalho E.M., et al. Identification of paramyosin T cell epitopes associated with human resistance to Schistosoma mansoni reinfection. Clin Exp Immunol 2005, 142:539-547.
145. Moser D., Tendler M., Griffiths G., Klinkert M.Q. A 14-kDa Schistosoma mansoni polypeptide is homologous to a gene family of fatty acid binding proteins. J Biol Chem 1991, 266:8447-8454.
146. Harn D.A., Mitsuyama M., Huguenel E.D., David J.R. Schistosoma mansoni: detection by monoclonal antibody of a 22,000-dalton surface membrane antigen which may be blocked by host molecules on lung stage parasites. J Immunol 1985, 135:2115-2120.
147. Reynolds S.R., Shoemaker C.B., Harn D.A. T and B cell epitope mapping of Sm23, an integral membrane protein of Schistosoma mansoni. J Immunol 1992, 149:3995-4001.
148. Koster B., Hall M.R.T., Strand M. Schistosoma mansoni: immuno-reactivity of human sera with the surface antigen Sm23. Exp Parasitol 1993, 77:282-294.
149. Karcz S.R., Podesta R.B., Siddiqui A.A., Dekaban G.A., Strejan G.H., Clarke M.W. Molecular cloning and sequence analysis of a calcium-activated neutral protease (calpain) from Schistosoma mansoni. Mol Biochem Parasitol 1991, 49:333-336.
150. Goudot-Crozel V., Caillol D., Djabali M., Dessein A.J. The major parasite surface antigen associated with human resistance to schistosomiasis is a 37-kD glyceraldehyde-3P-dehydrogenase. J Exp Med 1989, 170:2065-2080.
151. Charrier-Ferrara S., Caillol D., Goudot-Crozel V. Complete sequence of the Schistosoma mansoni glyceraldehyde-3-phosphate dehydrogenase gene encoding a major surface antigen. Mol Biochem Parasitol 1992, 56:339-343.
152. El Ridi R., Abdel Tawab N., Guirguis N. Schistosoma mansoni: identification and protective immunity of adult worm antigens recognized by T lymphocytes of outbred Swiss mice immunized with irradiated cercariae. Exp Parasitol 1993, 76:265-277.
153. Osman A., El Ridi R., Guirguis N., Dean D.A. Identification of Schistosoma mansoni antigens recognized by T cells of C57BL/6 mice immunized with gamma-irradiated cercariae. J Parasitol 1994, 80:421-431.
154. Osman A, El Ridi R, Guirguis N, Dean DA. Identification of Schistosoma mansoni antigens recognized by spleen cells of C57B1/6 mice immunized with ultraviolet-irradiated cercariae. Int J Parasitol 194;24:943-50.
155. Abdel Tawab N. Identification and molecular characterization of protective antigens against murine Schistosomiasis mansoni. Ph.D thesis. Faculty of Science, Cairo University; 1994. p. 280.
156. El Gengehi N., El Ridi R., Tawab N.A., El Demellawy M., Mangold B.L. A Schistosoma mansoni 62-kDa band is identified as an irradiated vaccine T-cell antigen and characterized as calreticulin. J Parasitol 2000, 86:993-1000.
157. Al-Sherbiny M., Osman A., Barakat R., El Morshedy H., Bergquist R., Olds R. In vitro cellular and humoral responses to Schistosoma mansoni vaccine candidate antigens. Acta Trop 2003, 88:117-130.
158. Ribeiro de Jesus A., Araújo I., Bacellar O., Magalhães A., Pearce E., Harn D., et al. Human immune responses to Schistosoma mansoni vaccine candidate antigens. Infect Immun 2000, 68:2797-2803.
159. Todd C.W., Colley D.G. Practical and ethical issues in the development of a vaccine against Schistosomiasis mansoni. Am J Trop Med Hyg 2002, 66:348-358.
160. Tendler M., Simpson A.J. The biotechnology-value chain: development of Sm14 as a schistosomiasis vaccine. Acta Trop 2008, 108:263-266.
161. Siddiqui A.A., Ahmad G., Damian R.T., Kennedy R.C. Experimental vaccines in animal models for schistosomiasis. Parasitol Res 2008, 102:825-833.
162. Ahmad G., Zhang W., Torben W., Ahrorov A., Damian R.T., Wolf R.F., et al. Preclinical prophylactic efficacy testing of Sm-p80-based vaccine in a nonhuman primate model of Schistosoma mansoni infection and immunoglobulin G and E responses to Sm-p80 in human serum samples from an area where schistosomiasis is endemic. J Infect Dis 2011, 204:1437-1449.
163. El Ridi R., Mahrous A., Afifi A., Montash M., Velek J., Jezek J. Human and murine humoral immune recognition of multiple peptides from Schistosoma mansoni glyceraldehyde 3-P dehydrogenase is associated with resistance to Schistosomiasis. Scand J Immunol 2001, 54:477-485.
164. Tallima H., Montash M., Veprek P., Velek J., Jezek J., El Ridi R. Differences in immunogenicity and vaccine potential of peptides from Schistosoma mansoni glyceraldehyde 3- phosphate dehydrogenase. Vaccine 2003, 21:3290-3300.
165. El Ridi R., Montash M., Tallima H. Immunogenicity and vaccine potential of di- peptidic multiple antigen peptides from Schistosoma mansoni glyceraldehyde 3-phosphate dehydrogenase. Scand J Immunol 2004, 60:392-402.
166. Veprek P., Jezek J., Velek J., Tallima H., Montash M., El Ridi R. Peptides and multiple antigen peptides from Schistosoma mansoni glyceraldehyde 3-phosphate dehydrogenase: preparation, immunogenicity and immunoprotective capacity in C57BL/6 mice. J Pept Sci 2004, 10:350-362.
167. Skelly P.J., Tielens A.G.M., Shoemaker C.B. Glucose transport and metabolism in mammalian-stage schistosomes. Parasitol Today 1998, 14:402-406.
168. Mahana NA. Human and murine immune responses to the Schistosoma mansoni glucose transporter. Ph.D thesis. Faculty of Science, Cairo University. p. 240.
169. Tran M.H., Pearson M.S., Bethony J.M., Smyth D.J., Jones M.K., Duke M., et al. Tetraspanins on the surface of Schistosoma mansoni are protective antigens against schistosomiasis. Nat Med 2006, 12:835-840.
170. Cai P., Bu L., Wang J., Wang Z., Zhong X., Wang H. Molecular characterization of Schistosoma japonicum tegument protein tetraspanin-2: sequence variation and possible implications for immune evasion. Biochem Biophys Res Commun 2008, 372:197-202.
171. Zhang W., Li J., Duke M., Jones M.K., Kuang L., Zhang J., et al. Inconsistent protective efficacy and marked polymorphism limits the value of Schistosoma japonicum tetraspanin-2 as a vaccine target. PLoS Negl Trop Dis 2011, 5:e1166.
172. Cupit PM, Steinauer ML, Tonnessen BW, Eric Agola L, Kinuthia JM, Mwangi IN, et al. Polymorphism associated with the Schistosoma mansoni tetraspanin-2 gene. Int J Parasitol 2011; 41:1249-52.
173. Pearson M.S., Pickering D.A., McSorley H.J., Bethony J.M., Tribolet L., Dougall A.M., et al. Enhanced protective efficacy of a chimeric form of the schistosomiasis vaccine antigen Sm-TSP-2. PLoS Negl Trop Dis 2012, 6:e1564.
174. McManus D.P., Loukas A. Current status of vaccines for schistosomiasis. Clin Microbiol Rev 2008, 21:225-242.
175. Keating J.H., Wilson R.A., Skelly P.J. No overt cellular inflammation around intravascular schistosomes in vivo. J Parasitol 2006, 92:1365-1369.
176. Loukas A., Tran M., Pearson M.S. Schistosome membrane proteins as vaccines. Int J Parasitol 2007, 37:257-263.
177. Tallima H., El Ridi R. Schistosoma mansoni glyceraldehyde 3-phosphate dehydrogenase is a lung-stage schistosomula surface membrane antigen. Folia Parasitol (Praha) 2008, 55:180-186.
178. El Ridi R., Tallima H. Schistosoma mansoni ex vivo lung-stage larvae excretory-secretory antigens as vaccine candidates against schistosomiasis. Vaccine 2009, 27:666-673.
179. Harrop R., Wilson R.A. Protein synthesis and release by cultured schistosomula of Schistosoma mansoni. Parasitology 1993, 107:265-274.
180. Harrop R., Coulson P.S., Wilson R.A. Characterization, cloning and immunogenicity of antigens released by lung-stage larvae of Schistosoma mansoni. Parasitology 1999, 118:583-594.
181. Curwen R.S., Ashton P.D., Johnston D.A., Wilson R.A. The Schistosoma mansoni soluble proteome: a comparison across four life-cycle stages. Mol Biochem Parasitol 2004, 138:57-66.
182. Knudsen G.M., Medzihradszky K.F., Lim K.C., Hansell E., McKerrow J.H. Proteomic analysis of Schistosoma mansoni cercarial secretions. Mol Cell Proteomics 2005, 4:1862-1875.
183. Curwen R.S., Ashton P.D., Sundaralingam S., Wilson R.A. Identification of novel proteases and immunomodulators in the secretions of schistosome cercariae that facilitate host entry. Mol Cell Proteomics 2006, 5:835-844.
184. Kroczek R.A., Mages H.W., Hutloff A. Emerging paradigms of T-cell co-stimulation. Curr Opin Immunol 2004, 16:321-327.
185. Pearce E.J., Caspar P., Grzych J.M., Lewis F.A., Sher A. Downregulation of Th1 cytokine production accompanies induction of Th2 responses by a parasitic helminth, Schistosoma mansoni. J Exp Med 1991, 173:159-166.
186. Coulson P.S. The radiation-attenuated vaccine against schistosomes in animal models: paradigm for a human vaccine?. Adv Parasitol 1997, 39:271-336.
187. Reis E.A., Mauadi Carmo T.A., Athanazio R., Reis M.G., Harn D.A. Schistosoma mansoni triose phosphate isomerase peptide MAP4 is able to trigger naïve donor immune response towards a type-1 cytokine profile. Scand J Immunol 2008, 68:169-176.
188. El Ridi R., Tallima H., Mahana N., Dalton J.P. Innate immunogenicity and in vitro protective potential of Schistosoma mansoni lung schistosomula excretory-secretory candidate vaccine antigens. Microbes Infect 2010, 12:700-709.
189. Dale D.C., Boxer L., Liles W.C. The phagocytes: neutrophils and monocytes. Blood 2008, 112:935-945.
190. Hickey M., Kubes P. Intravascular immunity: the host-pathogen encounter in blood vessels. Nat Rev Immunol 2009, 9:364-375.
191. Wynn T.A., Oswald I.P., Eltoum I.A., Caspar P., Lowenstein C.J., Lewis F.A., et al. Elevated expression of Th1 cytokines and nitric oxide synthase in the lungs of vaccinated mice after challenge infection with Schistosoma mansoni. J Immunol 1994, 153:5200-5209.
192. Ahmed S.F., Oswald I.P., Caspar P., Hieny S., Keefer L., Sher A., et al. Developmental differences determine larval susceptibility to nitric oxide-mediated killing in a murine model of vaccination against Schistosoma mansoni. Infect Immun 1997, 65:219-226.
193. Tallima H., Salah M., Guirguis F.R., El Ridi R. Transforming growth factor-β and Th17 responses in innate resistance to murine Schistosomiasis mansoni. Cytokine 2009, 48:239-245.
194. Saadi S., Wrenshall L.E., Platt J.L. Regional manifestations and control of the immune system. FASEB J 2002, 16:849-856.
195. Humphreys N.E., Xu D., Hepworth M.R., Liew F.Y., Grencis R.K. IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J Immunol 2008, 180:2443-2449.
196. Saenz S.A., Taylor B.C., Artis D. Welcome to the neighborhood: epithelial cell-derived cytokines license innate and adaptive immune responses at mucosal sites. Immunol Rev 2008, 226:172-190.
197. Tang H., Cao W., Kasturi S.P., Ravindran R., Nakaya H.I., Kundu K., et al. The T helper type 2 response to cysteine proteases requires dendritic cell-basophil cooperation via ROS-mediated signaling. Nat Immunol 2010, 11:608-617.
198. Siracusa M.C., Saenz S.A., Hill D.A., Kim B.S., Headley M.B., Doering T.A., et al. TSLP promotes interleukin-3-independent basophil haematopoiesis and type 2 inflammation. Nature 2011, 477:229-233.
199. Neill D.R., McKenzie A.N. Nuocytes and beyond: new insights into helminth expulsion. Trends Parasitol 2011, 27:214-221.
200. El Ridi R, Tallima H. Vaccine-induced protection against murine Schistosomiasis mansoni with larval excretory-secretory antigens and papain or type-2 cytokines. J Parasitol 2013;99:194-202.